OncoMatch/Clinical Trials/NCT05557838

Study of Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With Unresectable Hepatocellular Carinoma

Is NCT05557838 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including Durvalumab and Tremelimumab for hepatocellular carcinoma.

Phase 3RecruitingAstraZenecaNCT05557838Data as of May 2026

Treatment: Durvalumab · Tremelimumab — This is a prospective, open label, multi-center, interventional study to assess the safety and efficacy of Druvalumab plus Tremelimumab as first-line treatment in Chinese patients with unresectable hepatocellular carcinoma.

Check if I qualify

Extracted eligibility criteria

Cancer type

Hepatocellular Carcinoma

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Lab requirements

Liver function

child-pugh score class a or b

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify